<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To evaluate the efficacy of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CYA) regimens in preventing moderate to severe <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD), 25 patients received immunosuppressive therapy consisting of either CYA and <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> or CYA and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) and the incidence and severity of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD was compared </plain></SENT>
<SENT sid="1" pm="."><plain>These patients had <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and received bone marrow transplants (BMT) from genotypically HLA-identical siblings </plain></SENT>
<SENT sid="2" pm="."><plain>The incidence of grade I-IV <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD in patients on the CYA/<z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> regimen was 64% (7 of 11) compared with 50% (7 of 14) in those on the CYA/MTX regimen </plain></SENT>
<SENT sid="3" pm="."><plain>Five of 11 patients with the CYA/<z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> regimen developed moderate to severe <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (grade II-IV), fatal in 3 cases </plain></SENT>
<SENT sid="4" pm="."><plain>No patient on the CYA/MTX regimen developed moderate to severe <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD </plain></SENT>
<SENT sid="5" pm="."><plain>Engraftment was faster in the CYA/<z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> group than in the CYA/MTX group </plain></SENT>
<SENT sid="6" pm="."><plain>The incidence of toxicity observed soon after BMT was comparable between groups </plain></SENT>
<SENT sid="7" pm="."><plain>The CYA/MTX regimen may be superior to the CYA/<z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> regimen for preventing moderate to severe <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD </plain></SENT>
</text></document>